November 18, 2026
Health news, explained with evidence
LIVE
Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine

Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma

❤️ Conditions & Care 2 min read 👁 0

Researchers have identified a specific RNA signature in blood plasma that may help predict how well lymphoma patients respond to CAR T-cell therapy.

Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma❤️Conditions & Care

Photo: Medical Xpress

Key points

  • Cell-free RNA in blood plasma can act as a proxy for the tumor microenvironment.
  • Patients with a specific 'lymph node-like' genetic signature showed an 80% lower risk of cancer progression.
  • The test offers a non-invasive alternative to bone marrow or tissue biopsies.

A collaborative study between Cornell University and the Dana-Farber Cancer Institute suggests that a simple blood test could identify which patients are most likely to remain in remission following CAR T-cell therapy for large B-cell lymphoma. Published in Cell Reports Medicine, the findings indicate that fragments of cell-free RNA circulating in the blood can reveal the state of a tumor's local environment, providing a non-invasive alternative to traditional tissue biopsies.

The study analyzed plasma samples from 91 patients, revealing that those with a specific genetic signature—resembling the structure of a lymph node—had an 80% lower risk of cancer progression one year after treatment. Unlike previous methods that required invasive tissue sampling, this plasma-based approach reflects the tumor's microenvironment directly. Researchers noted that the signature was not found in circulating immune cells, suggesting it is a unique indicator of tissue-level activity.

While CAR T-cell therapy has significantly improved outcomes for blood cancer patients, nearly half of those treated either do not respond or experience a relapse within a year. This new diagnostic tool aims to address that uncertainty. However, as this research is based on observational analysis of patient cohorts, further clinical validation is required before it can be implemented in standard medical practice. Patients should always consult with their oncology care team regarding individual treatment plans and diagnostic options.

What to know: High levels of a specific RNA signature in blood plasma were linked to better long-term outcomes in lymphoma patients undergoing CAR T-cell therapy, offering a potential non-invasive way to predict treatment success.

Source Medical Xpress — medicalxpress.com/news/2026-11-blood-reveal-lymphoma-patients-immunothe… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.